NO20073942L - Farmasoytiske sammensetninger for behandling av sykdommer assosiert med NF-KB-aktivitet - Google Patents

Farmasoytiske sammensetninger for behandling av sykdommer assosiert med NF-KB-aktivitet

Info

Publication number
NO20073942L
NO20073942L NO20073942A NO20073942A NO20073942L NO 20073942 L NO20073942 L NO 20073942L NO 20073942 A NO20073942 A NO 20073942A NO 20073942 A NO20073942 A NO 20073942A NO 20073942 L NO20073942 L NO 20073942L
Authority
NO
Norway
Prior art keywords
activity
treatment
pharmaceutical compositions
diseases associated
effected
Prior art date
Application number
NO20073942A
Other languages
English (en)
Norwegian (no)
Inventor
David Wallach
Parameswaran Ramakrishnan
Taisia Shmushkovich
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of NO20073942L publication Critical patent/NO20073942L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20073942A 2004-12-27 2007-07-27 Farmasoytiske sammensetninger for behandling av sykdommer assosiert med NF-KB-aktivitet NO20073942L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL16600604A IL166006A0 (en) 2004-12-27 2004-12-27 Pharmaceutical compositions for treating diseases associated with nf-kb activity
PCT/IL2005/001335 WO2006070348A1 (en) 2004-12-27 2005-12-11 PHARMACEUTICAL COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH NF-κB ACTIVITY

Publications (1)

Publication Number Publication Date
NO20073942L true NO20073942L (no) 2007-09-27

Family

ID=36072106

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073942A NO20073942L (no) 2004-12-27 2007-07-27 Farmasoytiske sammensetninger for behandling av sykdommer assosiert med NF-KB-aktivitet

Country Status (9)

Country Link
US (1) US8338567B2 (ja)
EP (1) EP1838347B1 (ja)
JP (1) JP5686940B2 (ja)
AU (1) AU2005320905B2 (ja)
CA (1) CA2593035C (ja)
ES (1) ES2518340T3 (ja)
IL (2) IL166006A0 (ja)
NO (1) NO20073942L (ja)
WO (1) WO2006070348A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011090159A1 (ja) 2010-01-22 2011-07-28 独立行政法人科学技術振興機構 蛋白質の分解活性を測定するためのプローブ試薬
EP3431493A1 (en) * 2013-09-03 2019-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for inducing senescence in cancer
US12059413B2 (en) 2016-11-02 2024-08-13 The Research Foundation For The State University Of New York Methods of inhibiting viruses using compositions targeting TSG101-ubiquitin interaction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US5843721A (en) * 1997-07-03 1998-12-01 Tularik Inc. Nucleic acids encoding human NIK protein
US6265538B1 (en) 1998-02-27 2001-07-24 The Regents Of The University Of California Inhibitor of the inflammatory response induced by the TNFA and IL-1
ITMI20010402U1 (it) 2001-07-18 2003-01-18 Valerio Leccacorvi Rivestimento per le superfici di una piscina
CA2482387C (en) * 2002-04-18 2015-03-03 Yeda Research And Development Co. Ltd Derivatives of the nf-kappab inducing enzyme, their preparation and use

Also Published As

Publication number Publication date
AU2005320905A1 (en) 2006-07-06
ES2518340T3 (es) 2014-11-05
EP1838347B1 (en) 2014-10-01
JP2008525427A (ja) 2008-07-17
IL183926A (en) 2012-02-29
EP1838347A1 (en) 2007-10-03
IL183926A0 (en) 2007-10-31
IL166006A0 (en) 2006-01-15
JP5686940B2 (ja) 2015-03-18
AU2005320905B2 (en) 2011-03-17
US20090098106A1 (en) 2009-04-16
US8338567B2 (en) 2012-12-25
WO2006070348A1 (en) 2006-07-06
CA2593035C (en) 2014-10-14
CA2593035A1 (en) 2006-07-06

Similar Documents

Publication Publication Date Title
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
NO20073699L (no) Stabile protaglandin-inneholdende preparater
EA200600414A1 (ru) ПРОИЗВОДНЫЕ БОРОНОВОЙ КИСЛОТЫ (ВАРИАНТЫ), ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, КОМПОЗИЦИЯ ДЛЯ ИНГИБИРОВАНИЯ АКТИВНОСТИ NF-kB И ДЕГРАДАЦИИ БЕЛКА И СПОСОБЫ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ (ВАРИАНТЫ)
EA200971053A1 (ru) Способы лечения кожных язв
NO20083885L (no) Fremgangsmate for behandling av inflammatoriske sykdommer
ATE429430T1 (de) Stoffwechselmodulatoren und behandlung damit verbundener erkrankungen
NO20053678L (no) Kombinasjonsterapi for behandling av immuninflammatoriske forstyrrelser
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
NO20055129L (no) Fenylsubstituerte karboksylsyrer
NO20081975L (no) Diarylamin-inneholdende forbindelser og sammensetninger, og deres anvendelse som modulatorer av C-kit-reseptorer
AR056824A1 (es) Tableta de neramexano con matriz de liberacion modificada
NO20090469L (no) Substituerte piperidiner som oker P53-aktiviteten, og anvendelse derav
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
AR049955A1 (es) Composiciones y metodos para el tratamiento de trastornos metabolicos
IN2015DN00376A (ja)
UY32591A (es) Inhibidores ciclicos de 11beta-hidroxiesteroide deshidrogenasa 1
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
RS52825B (en) PROCEDURES FOR THE TREATMENT OF DISORDERS OR DISEASES RELATED TO HYPERLIPIDEMIA AND HYPERHOLESTEROLEMIA WITH MINIMIZATION OF ADVERSE EFFECTS
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
DE502006006466D1 (de) Eisen(iii) komplex-verbindungen zur oralen behandlung von eisenmangel bei patienten mit chronischen entzündlichen darmerkrankungen
RS52867B (en) GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application